METabolic EXplorer Bundle
Who Really Owns METabolic EXplorer?
Unraveling the METabolic EXplorer SWOT Analysis and its ownership structure is key to understanding its trajectory in the burgeoning industrial biotechnology landscape. The company, listed on Euronext Paris under the ticker METEX, has undergone significant changes, particularly with the acquisition by Avril Services in July 2024. This pivotal shift warrants a deep dive into the current METEX shareholders and the company's future.
This exploration into METEX ownership will reveal the influence of key investors and the impact of the Avril Services acquisition. We'll examine the evolution of METabolic EXplorer, from its founding by Benjamin Gonzalez to its current status as a publicly traded entity. Understanding the current owners of METabolic EXplorer is crucial for anyone looking to invest or simply understand the strategic direction of this innovative company.
Who Founded METabolic EXplorer?
The story of METabolic EXplorer (METEX) begins with its founder, Benjamin Gonzalez, who established the company in 1999. His vision centered on leveraging fermentation processes as a sustainable alternative to traditional petrochemical production. This innovative approach aimed to create eco-friendly solutions for various everyday products.
The early stages of METabolic EXplorer were significantly shaped by its incubation at Auvergne University. This partnership provided essential resources, including laboratory facilities, technical expertise, and administrative support. This environment was crucial for nurturing the company's initial research and development efforts.
The initial aim of METabolic EXplorer was to develop bio-based industrial processes, which was driven by Benjamin Gonzalez. The company's journey from a university-incubated project to a publicly listed entity indicates a progressive expansion of its ownership base, although precise details of early shareholding are not available.
Foundation
METabolic EXplorer was founded in 1999 by Benjamin Gonzalez.
Early Support
The company benefited from incubation at Auvergne University.
Public Listing
METabolic EXplorer went public on April 5, 2007, with an IPO price of 8.40 euros.
Initial Focus
The company's primary focus was on bio-based industrial processes.
Ownership Details
While specific details on the initial equity split among founders are not publicly available, the company's growth from its inception to its public listing suggests a broadening of its METEX shareholders base. Investors interested in learning more about the company's strategic direction might find insights in the Marketing Strategy of METabolic EXplorer.
- The company's IPO in 2007 marked a significant step in its ownership structure.
- The transition from a university-incubated project to a publicly traded company indicates a gradual increase in METEX ownership.
- Information regarding the current METabolic EXplorer investors and major METEX shareholders can be found in the company's financial reports.
- The company's early focus on sustainable solutions has shaped its long-term strategy.
METabolic EXplorer SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has METabolic EXplorer’s Ownership Changed Over Time?
The ownership structure of METabolic EXplorer has experienced significant shifts since its initial public offering on April 5, 2007. The company's market capitalization currently stands at approximately €6.16 million as of May 2025. A key event impacting ownership was the July 2024 acquisition of METEX NØØVISTAGO and parts of METEX's commercial and R&D operations by Avril Services, approved by the Paris Commercial Court on July 12, 2024. This acquisition, in partnership with the SPI investment fund managed by BPI France, aimed to preserve jobs and maintain a European production base.
Prior to the Avril Services acquisition, Bpifrance, through its SPI fund and BEI - Sociétés de Projets Industriels, held a substantial stake in METabolic EXplorer. As of December 2022, SPI held 25.93% of the company's capital, demonstrating Bpifrance's role as a major institutional investor. These changes reflect the evolving landscape of METEX ownership and the strategic moves made to ensure the company's operational continuity. The acquisition by Avril Services and the involvement of Bpifrance highlight the importance of strategic partnerships in the company's development.
| Key Dates | Event | Impact on Ownership |
|---|---|---|
| April 5, 2007 | Initial Public Offering (IPO) | Established initial shareholder base. |
| July 12, 2024 | Avril Services Acquisition | Avril Services, with SPI (BPI France), took over operations, impacting METEX shareholders. |
| December 2022 | Bpifrance Stake | SPI held 25.93% of the company's capital, reflecting significant institutional investment. |
As of March 31, 2024, METabolic EXplorer had 50,919,133 shares outstanding. The company's 2024 revenue was €14.5 million, with negative net income and a debt-to-equity ratio of 0.75 in Q1 2025. These financial figures underscore the need for strategic restructuring, as seen in the recent asset sales and ownership changes. For those interested in understanding the target market of the company, further insights can be found in this article: Target Market of METabolic EXplorer.
Ownership Insights
Understanding METEX ownership is crucial for investors and stakeholders.
- Avril Services and BPI France are key players in the current ownership structure.
- Bpifrance has historically held a significant stake, influencing METEX shareholders.
- The company's financial performance has driven recent strategic changes.
- METabolic EXplorer stock performance is impacted by these ownership dynamics.
METabolic EXplorer PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on METabolic EXplorer’s Board?
As of October 2024, the leadership of METabolic EXplorer (METEX) includes Benjamin Gonzalez as Chairman and Chief Executive Officer. Other key executives at the time were Rudolph Hidalgo as Deputy General Manager, Laurent Bastian as Chief Financial Officer, Laurence Caron as Chief Human Resources Officer, and Maria Wiltz as Chief Strategy and Development Officer. The company's structure reflects its status as a publicly listed entity on Euronext Paris, which influences its governance and shareholder rights.
Understanding the current METEX ownership structure is crucial for METabolic EXplorer investors. While specific details about board members and their connections to major shareholders aren't fully available in the latest reports, the company generally operated under a one-share-one-vote system. This is typical for publicly traded companies unless otherwise stated in their articles of association. As of March 31, 2024, the company had 50,919,133 shares and theoretical voting rights of 52,823,299.
| Role | Name | Title |
|---|---|---|
| Chairman & CEO | Benjamin Gonzalez | Chief Executive Officer |
| Deputy General Manager | Rudolph Hidalgo | Deputy General Manager |
| Chief Financial Officer | Laurent Bastian | Chief Financial Officer |
| Chief Human Resources Officer | Laurence Caron | Chief Human Resources Officer |
| Chief Strategy and Development Officer | Maria Wiltz | Chief Strategy and Development Officer |
Recent events, especially the sale of key assets to Avril Services in July 2024, have significantly impacted the decision-making authority within the METabolic EXplorer company. The Paris Commercial Court's approval of the sale and the subsequent judicial liquidation of METEX NØØVISTAGO and METabolic EXplorer indicate a shift in control. This process has effectively superseded prior governance arrangements, leading to the delisting of shares from Euronext, which will have zero value for METEX shareholders.
Key Takeaways on METEX Governance
The leadership team of METabolic EXplorer included Benjamin Gonzalez as CEO as of October 2024.
- The company's structure generally followed a one-share-one-vote system.
- Financial difficulties led to asset sales and judicial liquidation.
- Shareholders will not receive value due to the delisting.
- For more details, you can check out this article about METabolic EXplorer.
METabolic EXplorer Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped METabolic EXplorer’s Ownership Landscape?
The ownership profile of METabolic EXplorer has undergone significant changes in the last few years, culminating in a restructuring in 2024. A major shift occurred on July 16, 2024, when Avril Services acquired METEX NØØVISTAGO and parts of METEX's commercial and R&D operations. This acquisition, approved by the Paris Commercial Court, involved Avril, a French agri-food group, and the investment fund SPI, managed by BPI France. This move aimed to preserve jobs and maintain an industrial presence in the animal feed sector. If you are looking for more details about the company, you can check out Brief History of METabolic EXplorer.
Prior to the acquisition, in March 2024, insolvency proceedings were initiated for METabolic EXplorer and its industrial affiliates, METEX NØØVISTA and METEX NØØVISTAGO. Subsequently, the Paris Commercial Court ordered the conversion of these receivership proceedings into judicial liquidation for both METEX NØØVISTAGO and METabolic EXplorer in July 2024. This resulted in the delisting of METabolic EXplorer shares from Euronext, leaving shareholders with no value due to the company's liabilities.
These events reflect broader industry trends, including challenges faced by smaller biotech companies. The biotech and chemical sectors saw M&A activity of $140 billion and $80 billion, respectively, in 2024, showing a move towards consolidation. While strategic partnerships previously boosted revenue by 15% in 2024, they were insufficient to prevent the judicial liquidation. The bio-based chemicals market, valued at $77.6 billion in 2024 and projected to reach $110.8 billion by 2029, highlights the potential but also the intense competition and capital requirements in this sector.
Key Development
Avril Services acquired METEX NØØVISTAGO and parts of METEX's operations in July 2024.
Financial Status
Judicial liquidation was ordered for METabolic EXplorer in July 2024, leading to delisting and zero value for METEX shareholders.
Industry Trends
The biotech and chemical sectors show a trend toward consolidation through M&A activity.
Market Potential
The bio-based chemicals market is valued at $77.6 billion in 2024 and is projected to reach $110.8 billion by 2029.
METabolic EXplorer Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of METabolic EXplorer Company?
- What is Competitive Landscape of METabolic EXplorer Company?
- What is Growth Strategy and Future Prospects of METabolic EXplorer Company?
- How Does METabolic EXplorer Company Work?
- What is Sales and Marketing Strategy of METabolic EXplorer Company?
- What is Brief History of METabolic EXplorer Company?
- What is Customer Demographics and Target Market of METabolic EXplorer Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.